Triple combination MPT vaginal microbicide using curcumin and efavirenz loaded lactoferrin nanoparticles

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lakshmi, Yeruva Samrajya ^a   Kumar, Prashant ^a   Kishore, Golla ^a   Bhaskar, C ^a   Kondapi, Anand K ^a  

^a UNIVERSITY OF HYDERABAD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BENZOXAZINE DERIVATIVE; CURCUMIN; EFAVIRENZ; LACTOFERRIN; NANOPARTICLE;

ANIMAL; CHEMICALLY INDUCED; CHEMOPROPHYLAXIS; DRUG EFFECTS; FEMALE; INTRAVAGINAL DRUG ADMINISTRATION; LACTOBACILLUS; MICROBIAL VIABILITY; PATHOLOGY; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES; RAT; VAGINITIS;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-INFECTIVE AGENTS; BENZOXAZINES; CHEMOPREVENTION; CURCUMIN; FEMALE; LACTOBACILLUS; LACTOFERRIN; MICROBIAL VIABILITY; NANOPARTICLES; PRE-EXPOSURE PROPHYLAXIS; RATS; VAGINITIS;

EID: 84966738225     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25479     Document Type: Article

References (56)

1. Singh, S., Sedgh, G., Hussain, R. Unintended pregnancy: worldwide levels, trends, and outcomes. Studies in family planning 41, 241-250 (2010).
2. Hill, K. et al. Estimates of maternal mortality worldwide between 1990 and 2005: an assessment of available data. Lancet 370, 1311-1319, doi: 10.1016/S0140-6736(07)61572-4 (2007).
3. Malcolm, R. K., Boyd, P., McCoy, C. F., Murphy, D. J. Beyond HIV microbicides: multipurpose prevention technology products. BJOG : an international journal of obstetrics and gynaecology 121 Suppl 5, 62-69, doi: 10.1111/1471-0528.12852 (2014).
4. Thurman, A. R., Clark, M. R., Doncel, G. F. Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infectious diseases in obstetrics and gynecology 2011, 1-10, doi: 10.1155/2011/429403 (2011).
5. Kizima, L. et al. A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV. Plos one 9, e94547, doi: 10.1371/journal. pone.0094547 (2014).
6. Liu, S., Lu, H., Neurath, A. R., Jiang, S. Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. Antimicrobial agents and chemotherapy 49, 1830-1836, doi: 10.1128/AAC.49.5.1830-1836.2005 (2005).
7. Nutan & Gupta, S. K. Microbicides: a new hope for HIV prevention. The Indian journal of medical research 134, 939-949, doi: 10.4103/0971-5916.92639 (2011).
8. D'Cruz, O. J., Uckun, F. M. Clinical development of microbicides for the prevention of HIV infection. Current pharmaceutical design 10, 315-336 (2004).
9. Veazey, R. S. Microbicide safety/efficacy studies in animals: macaques and small animal models. Current opinion in HIV and AIDS 3, 567-573, doi: 10.1097/COH.0b013e32830891bb (2008).
10. Abdool Karim, S. S. et al. Safety and effectiveness of Buffer Gel and 0.5% PRO2000 gel for the prevention of HIV infection in women. Aids 25, 957-966, doi: 10.1097/QAD.0b013e32834541d9 (2011).
11. Tao, W., Richards, C., Hamer, D. Enhancement of HIV infection by cellulose sulfate. AIDS research and human retroviruses 24, 925-929, doi: 10.1089/aid.2008.0043 (2008).
12. Adams, J. L., Kashuba, A. D. Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Best practice & research. Clinical obstetrics & gynaecology 26, 451-462, doi: 10.1016/j.bpobgyn.2012.01.004 (2012).
13. McGowan, I. Microbicides for HIV prevention: reality or hope? Current opinion in infectious diseases 23, 26-31, doi: 10.1097/QCO.0b013e328334fe70 (2010).
14. Hendrix, C. W., Cao, Y. J., Fuchs, E. J. Topical microbicides to prevent HIV: clinical drug development challenges. Annual review of pharmacology and toxicology 49, 349-375, doi: 10.1146/annurev.pharmtox.48.113006.094906 (2009).
15. Darroch, J. E., Frost, J. J. Women's interest in vaginal microbicides. Family planning perspectives 31, 16-23 (1999).
16. Bilensoy, E., Rouf, M. A., Vural, I., Sen, M., Hincal, A. A. Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole:beta-cyclodextrin complex. AAPS Pharm. Sci.Tech 7, E38, doi: 10.1208/pt070238 (2006).
17. Woolfson, A. D., Malcolm, R. K., Morrow, R. J., Toner, C. F., McCullagh, S. D. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. International journal of pharmaceutics 325, 82-89, doi: 10.1016/j.ijpharm.2006.06.026 (2006).
18. El-Kamel, A., Sokar, M., Naggar, V., Al Gamal, S. Chitosan and sodium alginate-based bioadhesive vaginal tablets. AAPS pharm sci 4, E44, doi: 10.1208/ps040444 (2002).
19. De Clercq, E. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Medicinal research reviews 20, 323-349 (2000).
20. Guo, L. et al. Curcumin protects microglia and primary rat cortical neurons against HIV-1 gp120-mediated inflammation and apoptosis. Plos one 8, e70565, doi: 10.1371/journal.pone.0070565 (2013).
21. Bhullar, K. S., Jha, A., Youssef, D., Rupasinghe, H. P. Curcumin and its carbocyclic analogs: structure-activity in relation to antioxidant and selected biological properties. Molecules 18, 5389-5404, doi: 10.3390/molecules18055389 (2013).
22. Rithaporn, T., Monga, M., Rajasekaran, M. Curcumin: a potential vaginal contraceptive. Contraception 68, 219-223 (2003).
23. Naz, R. K., Lough, M. L. Curcumin as a potential non-steroidal contraceptive with spermicidal and microbicidal properties. European journal of obstetrics, gynecology, and reproductive biology 176, 142-148, doi: 10.1016/j.ejogrb.2014.01.024 (2014).
24. Hatcher, H., Planalp, R., Cho, J., Torti, F. M., Torti, S. V. Curcumin: from ancient medicine to current clinical trials. Cellular and molecular life sciences : CMLS 65, 1631-1652, doi: 10.1007/s00018-008-7452-4 (2008).
25. Mudshinge, S. R., Deore, A. B., Patil, S., Bhalgat, C. M. Nanoparticles: Emerging carriers for drug delivery. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society 19, 129-141, doi: 10.1016/j.jsps.2011.04.001 (2011).
26. Krishna, A. D., Mandraju, R. K., Kishore, G., Kondapi, A. K. An efficient targeted drug delivery through apotransferrin loaded nanoparticles. Plos one 4, e7240, doi: 10.1371/journal.pone.0007240 (2009).
27. Mallipeddi, R., Rohan, L. C. Progress in antiretroviral drug delivery using nanotechnology. International journal of nanomedicine 5, 533-547 (2010).
28. Wahome, N. et al. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine. Chemical biology & drug design 80, 349-357, doi: 10.1111/j.1747-0285.2012.01423.x (2012).
29. Hu, K. et al. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease. International journal of pharmaceutics 415, 273-283, doi: 10.1016/j.ijpharm.2011.05.062 (2011).
30. Lohcharoenkal, W., Wang, L., Chen, Y. C., Rojanasakul, Y. Protein nanoparticles as drug delivery carriers for cancer therapy. BioMed research international 2014, 180549, doi: 10.1155/2014/180549 (2014).
31. Mamo, T. et al. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine 5, 269-285, doi: 10.2217/nnm.10.1 (2010).
32. Sripriyalakshmi, S., Jose, P., Ravindran, A., Anjali, C. H. Recent trends in drug delivery system using protein nanoparticles. Cell biochemistry and biophysics 70, 17-26, doi: 10.1007/s12013-014-9896-5 (2014).
33. Gandapu, U., Chaitanya, R. K., Kishore, G., Reddy, R. C., Kondapi, A. K. Curcumin-loaded apotransferrin nanoparticles provide efficient cellular uptake and effectively inhibit HIV-1 replication in vitro. Plos one 6, e23388, doi: 10.1371/journal.pone.0023388 (2011).
34. Weber, C., Coester, C., Kreuter, J., Langer, K. Desolvation process and surface characterisation of protein nanoparticles. International journal of pharmaceutics 194, 91-102 (2000).
35. Actor, J. K., Hwang, S. A., Kruzel, M. L. Lactoferrin as a natural immune modulator. Current pharmaceutical design 15, 1956-1973 (2009).
36. Lonnerdal, B. Nutritional roles of lactoferrin. Current opinion in clinical nutrition and metabolic care 12, 293-297, doi: 10.1097/MCO.0b013e328328d13e (2009).
37. Legrand, D., Elass, E., Carpentier, M., Mazurier, J. Lactoferrin: a modulator of immune and inflammatory responses. Cellular and molecular life sciences : CMLS 62, 2549-2559, doi: 10.1007/s00018-005-5370-2 (2005).
38. Ward, P. P., Uribe-Luna, S., Conneely, O. M. Lactoferrin and host defense. Biochemistry and cell biology = Biochimie et biologie cellulaire 80, 95-102 (2002).
39. Golla, K., Cherukuvada, B., Ahmed, F., Kondapi, A. K. Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats. Plos one 7, e51960, doi: 10.1371/journal.pone.0051960 (2012).
40. Cummins, J. E. Jr. et al. Detection of infectious human immunodeficiency virus type 1 in female genital secretions by a short-term culture method. Journal of clinical microbiology 41, 4081-4088 (2003).
41. Mitchell, C. et al. Detection of fastidious vaginal bacteria in women with HIV infection and bacterial vaginosis. Infectious diseases in obstetrics and gynecology 2009, 236919, doi: 10.1155/2009/236919 (2009).
42. Davis, K. R., Weller, S. C. The effectiveness of condoms in reducing heterosexual transmission of HIV. Family planning perspectives 31, 272-279 (1999).
43. Mansour, D., Inki, P., Gemzell-Danielsson, K. Efficacy of contraceptive methods: A review of the literature. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception 15, 4-16, doi: 10.3109/13625180903427675 (2010).
44. Mukandavire, Z., Garira, W. Sex-structured HIV/AIDS model to analyse the effects of condom use with application to Zimbabwe. Journal of mathematical biology 54, 669-699, doi: 10.1007/s00285-006-0063-5 (2007).
45. Padian, N. S. et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 370, 251-261, doi: 10.1016/S0140-6736(07)60950-7 (2007).
46. Gaur, P. K., Mishra, S., Bajpai, M., Mishra, A. Enhanced oral bioavailability of efavirenz by solid lipid nanoparticles: in vitro drug release and pharmacokinetics studies. BioMed research international 2014, 363404, doi: 10.1155/2014/363404 (2014).
47. Vajragupta, O., Boonchoong, P., Morris, G. M., Olson, A. J. Active site binding modes of curcumin in HIV-1 protease and integrase. Bioorganic & medicinal chemistry letters 15, 3364-3368, doi: 10.1016/j.bmcl.2005.05.032 (2005).
48. Berkhout, B. et al. Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides. Antiviral research 55, 341-355 (2002).
49. Harris, M. et al. Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future. AIDS research and treatment 2012, 595-762, doi: 10.1155/2012/595762 (2012).
50. Sehgal, R., Goyal, K., Sehgal, A. Trichomoniasis and lactoferrin: future prospects. Infectious diseases in obstetrics and gynecology 2012, 536037, doi: 10.1155/2012/536037 (2012).
51. Levay, P. F., Viljoen, M. Lactoferrin: a general review. Haematologica 80, 252-267 (1995).
52. Conneely, O. M. Antiinflammatory activities of lactoferrin. Journal of the American College of Nutrition 20, 389S-395S; discussion 396S-397S (2001).
53. Catalone, B. J. et al. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrobial agents and chemotherapy 48, 1837-1847 (2004).
54. Lackman-Smith, C. et al. Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrobial agents and chemotherapy 52, 1768-1781, doi: 10.1128/AAC.01328-07 (2008).
55. Bienvenu, E., Hoffmann, K. J., Ashton, M., Kayumba, P. C. A rapid and selective HPLC-UV method for the quantitation of efavirenz in plasma from patients on concurrent HIV/AIDS and tuberculosis treatments. Biomedical chromatography : BMC 27, 1554-1559, doi: 10.1002/bmc.2959 (2013).
56. Li, J. et al. A rapid and simple HPLC method for the determination of curcumin in rat plasma: assay development, validation and application to a pharmacokinetic study of curcumin liposome. Biomedical chromatography : BMC 23, 1201-1207, doi: 10.1002/bmc.1244 (2009).